Proteomics & Protein Research

Company researchers showed that the agents could selectively target single point mutations not associated with protein-binding pockets.

Avera Health will offer the TheraLink Assay to its employees and conduct studies to establish the clinical utility of the proteomic panel.

Interest in detection directly from specimens and antibiotic resistance is leading some researchers to look at methods likeREIMSand MRM-MS.

Looking at 20 cell lines and four tumor samples, they identified a variety of protein-defined breast cancer subtypes as well as potential drug targets.

The agency approved the Acquity UPLC I-Class IVD/Xevo TQ-S IVD LC-MS for clinical analysis of various targets.